Last viewed:
KMPH
Prices are updated after-hours
KMPH
|
$5.46
6.04%
0
|
Manufacturing
(0.0% 1d)
(0.7% 1m)
(0.0% 1y)
(0.0% 2d)
(0.0% 3d)
(0.7% 7d)
(NaN%
volume)
Earnings Calendar: 2023-03-30
Market Cap: $ 188,396,547
http://www.kempharm.com/
Sec
Filling
|
Patents
| 22 employees
(US) KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT™ (Ligand Activated Therapy) technology. KemPharm utilizes its proprietary LAT™ technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. KemPharm's prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, and stimulant use disorder. KemPharm's co-lead clinical development candidates for the treatment of ADHD, KP415 and KP484, are both based on a prodrug of d-methylphenidate, but have differing duration/effect profiles. In addition, KemPharm has received FDA approval for APADAZ®, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.
urea
treatment
profitable
add to watch list
Paper trade
email alert is off
Press-releases
Central Nervous System (CNS) Stimulant Drugs Market size is set to grow by USD 6.48 billion from 2023-2027, Rise in incidence of CNS disorders boost the market, Technavio
Published: 2024-04-10
(Crawled : 09:00)
- prnewswire.com
ALPMF
|
$9.17
43.47%
16K
|
Health Technology
| -9.51%
| O: -100.0%
H: NaN%
C: Infinity%
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
| -1.65%
| O: -0.01%
H: 0.0%
C: 0.0%
NVSEF
|
$93.6375
6.88%
82K
|
Health Technology
| -2.16%
| O: -1.67%
H: 0.0%
C: 0.0%
ALPMY
|
$9.47
-1.11%
520K
|
Manufacturing
| -9.26%
| O: -0.29%
H: 0.0%
C: -1.97%
VTRS
A
|
$11.25
1.17%
1.16%
4.7M
|
Health Technology
| -4.01%
| O: -0.6%
H: 1.03%
C: 0.52%
TMO
|
News
|
$544.78
0.6%
0.0%
1.7M
|
Health Technology
| -7.54%
| O: -2.01%
H: 0.0%
C: 0.0%
NVS
|
$94.36
1.93%
0.0%
2.3M
|
Health Technology
| -1.37%
| O: -1.16%
H: 0.0%
C: 0.0%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
| -2.59%
| O: -0.32%
H: 0.0%
C: 0.0%
JAZZ
|
$109.96
0.63%
0.63%
760K
|
Health Technology
| -4.92%
| O: -1.71%
H: 0.57%
C: 0.37%
disorders
system
set
market
Zevra Therapeutics Begins Trading as ZVRA
Published: 2023-03-01
(Crawled : 13:00)
- globenewswire.com
KMPH
|
$5.46
6.04%
0
|
Manufacturing
| Email alert
Add to watchlist
therapeutics
Zevra Therapeutics, a Rare Disease Therapeutics Company, Files Preliminary Proxy
Published: 2023-02-27
(Crawled : 22:00)
- globenewswire.com
KMPH
|
$5.46
6.04%
0
|
Manufacturing
| 0.68%
| O: 0.68%
H: 0.0%
C: 0.0%
rare
disease
therapeutics
Zevra Therapeutics Announces Arimoclomol Research Featured in Two Poster Presentations at the 19th Annual WORLDSymposium™ 2023
Published: 2023-02-24
(Crawled : 13:00)
- globenewswire.com
KMPH
|
$5.46
6.04%
0
|
Manufacturing
| 4.62%
| O: 2.04%
H: 0.0%
C: 0.0%
research
therapeutics
CORRECTION – KemPharm Announces Corporate Name Change to Zevra Therapeutics
Published: 2023-02-22
(Crawled : 14:00)
- globenewswire.com
KMPH
|
$5.46
6.04%
0
|
Manufacturing
| 10.51%
| O: 1.05%
H: 4.9%
C: 4.53%
change
therapeutics
KemPharm Partners with the Hypersomnia Foundation to Support Sleep Disorder Research and Advocacy
Published: 2023-01-18
(Crawled : 12:20)
- globenewswire.com
KMPH
|
$5.46
6.04%
0
|
Manufacturing
| 5.65%
| O: 7.62%
H: 3.67%
C: 2.67%
research
KemPharm Announces Promotion of Sven Guenther, Ph.D., to Chief Scientific Officer and Christal Mickle, M.A., to Chief Product Development Officer
Published: 2023-01-11
(Crawled : 13:00)
- globenewswire.com
KMPH
|
$5.46
6.04%
0
|
Manufacturing
| 30.89%
| O: 6.44%
H: 4.38%
C: 3.97%
KemPharm Announces Appointment of Christopher Posner as New Independent Director
Published: 2022-11-29
(Crawled : 13:00)
- globenewswire.com
ENDPQ
|
$0.0006
-50.0%
3.4K
|
n/a
| -95.92%
| O: 1.12%
H: 0.1%
C: -4.23%
KMPH
|
$5.46
6.04%
0
|
Manufacturing
| 24.0%
| O: -2.84%
H: 0.0%
C: 0.0%
BMY
|
$48.93
1.3%
0.0%
10M
|
Health Technology
| -38.17%
| O: -0.42%
H: 0.38%
C: 0.28%
CARA
|
$0.6816
-1.22%
-1.23%
350K
|
Health Technology
| -94.07%
| O: 0.27%
H: 0.72%
C: -1.25%
KemPharm Receives FDA Orphan Drug Designation for Serdexmethylphenidate (SDX) for the Treatment of Idiopathic Hypersomnia (IH)
Published: 2022-11-18
(Crawled : 13:00)
- globenewswire.com
KMPH
|
$5.46
6.04%
0
|
Manufacturing
| 24.52%
| O: -6.34%
H: 0.0%
C: 0.0%
treatment
fda
designation
drug
KemPharm to Present at the Canaccord Genuity 42nd Annual Growth Conference
Published: 2022-08-02
(Crawled : 12:00)
- globenewswire.com
KMPH
|
$5.46
6.04%
0
|
Manufacturing
| 7.88%
| O: -0.37%
H: 0.0%
C: 0.0%
conference
growth
See all
Last 15 days Sec forms
File Id
Form
Published Date
Transaction Date
Direction
Code
Amount Transacted
Owned Amount